Ly6/upar-related protein c4.4a as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 8, Issue 2, 2013, Pages 152-160

  Jacobsen, Benedikte ^a,b,g   Muley, Thomas ^c,h   Meister, Michael ^c,h   Dienemann, Hendrik ^d,h   Christensen, Ib Jarle ^a,b   Santoni Rugiu, Eric ^e   Lærum, Ole Didrik ^a,f   Ploug, Michael ^a,b,g  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Translational Research Unit   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e University of Copenhagen   (Denmark)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g Danish Chinese Centre for Proteases and Cancer   (Denmark)

^h German Center for Lung Research (DZL)   (Germany)

Author keywords

Biomarker; Histologic subtypes of adenocarcinomas; LYPD3; Non small cell lung cancer; Survival

Indexed keywords

PROTEIN; PROTEIN C4.4A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 84873098547     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318279d503     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
3. Tanoue LT. Staging of non-small cell lung cancer. Semin Respir Crit Care Med 2008;29:248-260.
4. Ettinger DS, Akerley W, Bepler G, et al.; NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801.
5. Jacobsen B, Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 2008;15:2559-2573.
6. Hansen LV, Gårdsvoll H, Nielsen BS, et al. Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor. Biochem J 2004;380(Pt 3):845-857.
7. Hansen LV, Skov BG, Ploug M, Pappot H. Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer. Lung Cancer 2007;58:260-266.
8. Rösel M, Claas C, Seiter S, Herlevsen M, Zöller M. Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor. Oncogene 1998;17:1989-2002.
9. Hansen LV, Laerum OD, Illemann M, Nielsen BS, Ploug M. Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma. Int J Cancer 2008;122:734-741.
10. Kriegbaum MC, Jacobsen B, Hald A, Ploug M. Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesis. J Histochem Cytochem 2011;59:188-201.
11. Würfel J, Seiter S, Stassar M, et al. Cloning of the human homologue of the metastasis-associated rat C4.4A. Gene 2001;262:35-41.
12. Heighway J, Knapp T, Boyce L, et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002;21:7749-7763.
13. Jacobsen B, Santoni-Rugiu E, Illemann M, Kriegbaum MC, Laerum OD, Ploug M. Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma. Int J Cancer 2012;130:2734-2739.
14. Gu Y, Lin S, Li JL, et al. Altered LKB1/CREB-regulated transcription coactivator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene 2012;31:469-479.
15. Gao Y, Ge G, Ji H. LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor. Protein Cell 2011;2:99-107.
16. Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659-3662.
17. Conde E, Suarez-Gauthier A, García-García E, et al. Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas. Hum Pathol 2007;38:1351-1360.
18. Ghaffar H, Sahin F, Sanchez-Cepedes M, et al. LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res 2003;9:2998-3003.
19. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
20. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438-1446.
21. Gårdsvoll H, Hansen LV, Joørgensen TJ, Ploug M. A new tagging system for production of recombinant proteins in Drosophila S2 cells using the third domain of the urokinase receptor. Protein Expr Purif 2007;52:384-394.
22. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
23. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011;6:1496-1504.
24. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-664.
25. Iwasaki T, Ohta M, Lefor AT, Kawahara K. Signet-ring cell carcinoma component in primary lung adenocarcinoma: potential prognostic factor. Histopathology 2008;52:639-640.
26. Noguchi M. Stepwise progression of pulmonary adenocarcinoma-clinical and molecular implications. Cancer Metastasis Rev 2010;29:15-21.
27. Wistuba II. Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med 2007;7:3-14.
28. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823-835.
29. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24:1679-1688.
30. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827.
31. Yatabe Y, Borczuk AC, Powell CA. Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer 2011;74:7-11.
32. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-790.
33. Yoshida A, Tsuta K, Watanabe S, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011;72:309-315.
34. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007;26:5911-5918.
35. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
36. Chen G, Kim S, Taylor JM, et al. Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol 2011;6:1481-1487.
37. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
38. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
39. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
40. A Service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/2012.
41. Ekman S, Wynes MW, Hirsch FR. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J Thorac Oncol 2012;7:947-953.